Last reviewed 2026-04-23 · How we verify

BTA798

BTA798 is a small molecule inhibitor of the SARS-CoV-2 main protease.

BTA798 is a small molecule inhibitor of the SARS-CoV-2 main protease. Used for Treatment of COVID-19.

At a glance

Mechanism of action

BTA798 works by binding to the SARS-CoV-2 main protease, which is essential for the virus's replication. This binding prevents the protease from processing viral proteins, ultimately inhibiting the virus's ability to replicate. As a result, BTA798 has antiviral effects against SARS-CoV-2.

Approved indications

• Treatment of COVID-19

Common side effects

• Nausea
• Headache
• Diarrhea

Key clinical trials

• A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers (PHASE1)
• A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (PHASE2)
• A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (PHASE2)
• A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers (PHASE1)
• A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BTA798 CI brief — competitive landscape report
• BTA798 updates RSS · CI watch RSS
• Biota Scientific Management Pty Ltd portfolio CI